Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA

NCT00843284

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neuropathic Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Clinical diagnosis of neuropathic pain and inclusion according to the current Summary of Product Characteristics.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- The patients were excluded according to the current Summary of Product
Characteristics.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Neuropathic PainEpidemiologic Multicentre Study of Neuropathic Post-surgical Pain
NCT00812734
  1. Clermont-Ferrand,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Neuropathic PainNeuropathic Pain Database
NCT00669006
  1. London, Ontario
ALL GENDERS
0+
years
MULTIPLE SITES
Neuropathic PainA Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain
NCT00301223
  1. Beijing,
  2. Cheng Du Si Chaun,
  3. Guang Zhou,
  4. Nan Jing, Jiang Su,
  5. Qing Dao Shan Dong,
  6. Shang Hai,
  7. Shanghai,
  8. Tian Jin,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Neuropathic PainEfficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
NCT00219544
  1. Calgary, Alberta
  2. Calgary, Alberta
  3. Calgary, Alberta
  4. Edmonton, Alberta
  5. Edmonton, Alberta
  6. Red Deer, Alberta
  7. Kelowna, British Columbia
  8. Vancouver, British Columbia
  9. Vancouver, British Columbia
  10. Winnipeg, Manitoba
  11. Winnipeg, Manitoba
  12. Winnipeg, Manitoba
  13. Halifax, Nova Scotia
  14. Kingston, Ontario
  15. London, Ontario
  16. Port Hope, Ontario
  17. Toronto, Ontario
  18. Charlottetown, Prince Edward Island
  19. Granby, Quebec
  20. Laval, Quebec
  21. Laval, Quebec
  22. Levis, Quebec
  23. Mirabel, Quebec
  24. Montreal, Quebec
  25. Montreal, Quebec
  26. Montreal, Quebec
  27. Sherbrooke, Quebec
  28. Sherbrook, Quebec
  29. Ste-Foy, Quebec
  30. Saskatoon, Saskatchewan
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA
Official Title Assessing the Treatment of Patients With Neuropathic Pain Using LYRICA; A Non Interventional Post-marketing Study (NI-PMS)
Brief Summary A Non-Interventional, Post-Marketing Surveillance (NI-PMS) study whose objectives were to assess the impact of pregabalin on subjects' pain, quality of sleep, and their general wellbeing, as well as the tolerance and safety of pregabalin in subjects with neuropathic pain.
Detailed Description A non-interventional study of patients diagnosed with neuropathic pain administered pregabalin and followed up for 8 weeks
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients with neuropathic pain
Condition Neuropathic Pain
Intervention Drug: Pregabalin
Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
Study Groups/Cohorts Patients with neuropathic pain
Intervention: Drug: Pregabalin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: March 12, 2009)
691
Original Actual Enrollment
 (submitted: February 12, 2009)
700
Actual Study Completion Date March 2008
Actual Primary Completion Date March 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Clinical diagnosis of neuropathic pain and inclusion according to the current Summary of Product Characteristics.

Exclusion Criteria:

  • The patients were excluded according to the current Summary of Product Characteristics.
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT00843284
Other Study ID Numbers A0081139
ATLAS
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2009